ong-term follow-up at 10-years of patients enrolled in the fingolimod Phase II program in relapsing multiple sclerosis

• Conditions: multiple sclerosis; MedDRA version: 16.1Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disorders; Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

• Registration Number: EUCTR2013-002660-17-IT
• Lead Sponsor: ovartis Farma SpA

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2014-02-17
• Last Update Posted: 11 April 2016

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 281

Inclusion Criteria

1. Written informed consent must be obtained before any assessment is performed
2. Randomized in study FTY720D2201 and received at least one dose of study drug
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 266
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 15

Exclusion Criteria

Patients not meeting the inclusion criteria are excluded.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified